Sai Life Sciences Limited

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding the allotment of 54,500 shares under Employees Stock Option Plan 2008.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, certifying the details of securities dematerialized/rematerialized during the quarter ended 30th September 2026.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the unaudited financial results for the second quarter and half year ending on 30th September 2026.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding allotment of 24,000 securities pursuant to ESOP/ESPS at its meeting held on September 18, 2026. The issued, subscribed, and paid-up equity share capital of the Company has increased from ₹21,23,94,217/- to ₹ 21,24,18,216/-.

Sai Life Sciences Limited

Sai Life Sciences Limited has submitted the Exchange a copy of the Scrutinizers report of the Annual General Meeting held on September 17, 2026, and informed the Exchange regarding voting results. All resolutions set out in the Notice of 27th AGM were passed with the requisite majority.

Sai Life Sciences Limited

Sai Life Sciences Limited held its 27th Annual General Meeting on September 17, 2026, through video conferencing. The meeting was attended by 94 members holding 7,76,98,047 equity shares. The notice of the meeting and the integrated annual report for the financial year 2025-2026 were sent electronically to members. The auditor's report and secretarial audit report were taken as read, with no qualifications, observations, or adverse comments. The register of directors and KMP, register of contracts, and compliance certificate were maintained in compliance with the Companies Act and SEBI regulations.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about the schedule of an Analyst / Institutional Investor Meeting to be held on September 18th, 2026, at Jefferies 5th India Forum in Gurgaon.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about the schedule of an Analyst / Institutional Investor Meeting to be held on September 14th, 2026, in New York.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding the allotment of 80,600 shares under Employees Stock Option Plan 2008 and Management Employee Stock Option Plan 2018.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 27th Annual General Meeting to be held through Video Conference/OAVM on September 17, 2026.

Sai Life Sciences Limited

Sai Life Sciences Limited has sent web link letters to shareholders whose email addresses are not registered with the company, registrar, or depository participant, containing the navigation path to access the Integrated Annual Report for FY 2025-26.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 17, 2026.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about the publication of a newspaper advertisement regarding the 27th Annual General Meeting (AGM) to be held on September 17, 2026, through video conference.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding 'Information relating to 27th Annual General Meeting (AGM) and Cut-off date for e-voting.' The 27th AGM will be held on September 17, 2026, through Video Conferencing, and members can exercise their right to vote electronically on all the resolutions set forth in the notice of 27th AGM.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about the Transcript of the Earnings conference call organized on 07 August 2026, post declaration of the Un-audited Financial Results of the Company for the quarter ended 30 June 2026.

Sai Life Sciences Limited

Sai Life Sciences Limited has published its un-audited financial results for the quarter ended June 30, 2026, which show a net profit of ₹291.0 crore, a 24% decrease from the same quarter last year. The company's total income from operations was ₹559.9 crore, a 16% decrease from the same quarter last year. The results were reviewed by the Audit Committee and approved by the Board of Directors on August 6, 2026.

Sai Life Sciences Limited

Crisil Ratings Limited, the monitoring agency, has submitted a report on the utilization of proceeds from Sai Life Sciences Limited's Initial Public Offer (IPO) for the quarter ended June 30, 2026. The report states that there are no deviations from the objects of the issue.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange about the link of recording of earnings call for the un-audited financial results of the company for the quarter ended on 30 June 2026.

Sai Life Sciences Limited

Sai Life Sciences Limited has released its Q1FY27 investor presentation, highlighting a 12% YoY revenue growth to ₹554 crore, with CRO business growing 24% YoY and CDMO business growing 15% YoY. The company has a strong pipeline with 33 active commercial molecules and 14 late-phase molecules. The company has also achieved an EcoVadis Platinum Rating 2026 and operationalized a new 100,000 sq. ft. R&D facility at Genome Valley, Hyderabad.

Sai Life Sciences Limited

Sai Life Sciences Limited has informed the Exchange regarding allotment of 18,700 securities pursuant to ESOP/ESPS at its meeting held on August 06, 2026.